NWI Management’s AstraZeneca AZN Stock Holding History

NWI Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100,000	Closed	-$13.3M	–	58
2022 Q1	$13.3M	Buy	+100,000	New	+$12M	1.52%	18

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NWI Management's AZN Position: Q2 2026 in Review

NWI Management held its AstraZeneca (AZN) position steady in Q2 2026 at 25,000 shares worth $4.74M. The position accounts for 0.22% of the portfolio, ranked #39.

NWI Management first reported a position in AZN in Q4 2020 and has held it in 23 quarters since. The position peaked at $19.8M in Q2 2022. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

NWI Management held 25,000 shares of AstraZeneca worth $4.74M as of Q2 2026.
NWI Management left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.22% of NWI Management's portfolio in Q2 2026, its #39 holding.
NWI Management first reported a position in AstraZeneca in Q4 2020 and has held it in 23 quarters since.
NWI Management's AstraZeneca position peaked at $19.8M in Q2 2022.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on NWI Management's 13F filing for Q2 2026, filed 14 Aug 2026.